BCTX BriaCell Therapeutics Corp.
USHealthcareAs of 2026-10-08
Why BCTX matters now
BriaCell Therapeutics Corp. (BCTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $3.92 with -2.13% on the session and $34.1M in market capitalization; recent performance reads 1-month -17.38% and YTD -59.21%.
The latest financial table shown here is Q3 2026, with revenue of $0.00, net income of $-7.2M, and EPS of $-0.99. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -567.2%.
The latest indexable market news headline is "BriaCell and BriaPro to Present Four Posters at SITC 2026 Annual Meeting" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.87
P/S
0.00
EV/EBITDA
0.04
DCF Value
$4.19
FCF Yield
-567.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-147.9%
ROA
-113.2%
ROIC
-136.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $0.00 | $-7.2M | $-0.99 |
| Q2 2026 | $0.00 | $-7.4M | $-2.62 |
| Q1 2026 | $0.00 | $-11.5M | $-4.35 |
| Q4 2025 | $0.00 | $-11.1M | $-5.87 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
1.64
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.